These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 27563805

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
    Ma Q, Min K, Wang T, Chen B, Wen Q, Wang F, Ji T, Gao S.
    Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
    [Abstract] [Full Text] [Related]

  • 3. Integrin Imaging with 99mTc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer.
    Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, Li S, Luo J, Luo Y, Cui Q, Zheng K, Liu Z, Shi J, Li F, Wang F, Zhu Z.
    Radiology; 2016 Dec; 281(3):958-966. PubMed ID: 27479638
    [Abstract] [Full Text] [Related]

  • 4. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
    Chen B, Zhao G, Ma Q, Ji B, Ji T, Xin H, Gao S.
    Int J Clin Exp Pathol; 2015 Dec; 8(12):16064-72. PubMed ID: 26884883
    [Abstract] [Full Text] [Related]

  • 5. ⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.
    Ji B, Chen B, Wang T, Song Y, Chen M, Ji T, Wang X, Gao S, Ma Q.
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1362-70. PubMed ID: 25947573
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
    Zhang RX, Cai DY, Hong TT, Wu XH, Hua D.
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Advantages of 99mTc-3PRGD2 SPECT over CT in the preoperative assessment of lymph node metastasis in patients with esophageal cancer.
    Lv N, Gao S, Bai L, Ji B, Xue J, Ge X, Chen B.
    Ann Nucl Med; 2019 Jan; 33(1):39-46. PubMed ID: 30218281
    [Abstract] [Full Text] [Related]

  • 10. 99mTc-3PRGD2 SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors.
    Xiao L, Yu S, Xu W, Sun Y, Xin J.
    Korean J Radiol; 2023 Nov; 24(11):1142-1150. PubMed ID: 37899523
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography.
    Chen G, Ouyang Z, Wang F, Wu H, Jia B, Chordia MD.
    Cancer Invest; 2017 Feb 07; 35(2):108-115. PubMed ID: 28135863
    [Abstract] [Full Text] [Related]

  • 12. Clinical Value of 99mTc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative 131I Whole-Body Scan and Elevated Thyroglobulin Level.
    Gao R, Zhang GJ, Wang YB, Liu Y, Wang F, Jia X, Liang YQ, Yang AM.
    Sci Rep; 2018 Jan 11; 8(1):473. PubMed ID: 29323252
    [Abstract] [Full Text] [Related]

  • 13. 99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma: A preliminary STROBE-compliant observational study.
    Yan B, Fu T, Liu Y, Wei W, Dai H, Fang W, Wang F.
    Medicine (Baltimore); 2018 Oct 11; 97(40):e12441. PubMed ID: 30290601
    [Abstract] [Full Text] [Related]

  • 14. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y, Yang M.
    DNA Cell Biol; 2018 Nov 11; 37(11):903-908. PubMed ID: 30277797
    [Abstract] [Full Text] [Related]

  • 15. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
    Lee JH, Lee HY, Ahn MJ, Park K, Ahn JS, Sun JM, Lee KS.
    Cancer Imaging; 2016 Mar 16; 16():5. PubMed ID: 26984681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
    Hsu KH, Huang YH, Tseng JS, Chen KC, Ku WH, Su KY, Chen JJW, Chen HW, Yu SL, Yang TY, Chang GC.
    Lung Cancer; 2019 Jan 16; 127():37-43. PubMed ID: 30642549
    [Abstract] [Full Text] [Related]

  • 20. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H, Wang Y, Su F, Li J, Gong P.
    Int J Clin Exp Pathol; 2015 Jan 16; 8(5):5577-83. PubMed ID: 26191267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.